GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: MK-1308 | MK1308
Compound class:
Antibody
Comment: Quavonlimab (MK-1308) is a humanized IgG1 anti-CTLA-4 monoclonal antibody [1]. It blocks the inhibitory CTLA-4/CD80/CD86 immune checkpoint, as a mechanism to reactivate anti-tumour immune surveillance.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR et al.. (2021)
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol, 32 (3): 395-403. [PMID:33276076] |
